vimarsana.com
Home
Live Updates
Mirati Therapeutics Provides Update on Regulatory Review in
Mirati Therapeutics Provides Update on Regulatory Review in
Mirati Therapeutics Provides Update on Regulatory Review in the European Union of KRAZATI (adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRAS G12C Mutation
SAN DIEGO and ZUG, Switzerland, July 21, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® , a commercial stage biotechnology company, today announced the European Medicine Agency's Committee for...
Related Keywords
United States ,
Switzerland ,
,
Linkedin ,
Exchange Commission ,
Facebook ,
Committee For Medicinal Products Human Use ,
Prnewswire Mirati Therapeutics Inc ,
European Medicine Agency ,
Nasdaq ,
Twitter ,
Mirati Therapeutics Inc ,
European Union ,
Medicinal Products ,
Human Use ,
Conditional Marketing Authorisation Application ,
Conditional Marketing ,
Conditional Marketing Authorisation ,
David Meek ,
Mirati Therapeutics ,
Accelerated Approval ,
Therapeutic Susceptibility ,
Mutant Cancers ,
Mouse Models ,
Brain Metastases ,
Preclinical Models ,
Clinical Data ,
Mutant Non Small Cell Lung ,
Clin Cancer ,
Published April ,
Markets ,